Niemann-Pick Disease Type A (NP-A) and Niemann-Pick Disease Type B (NP-B) were once thought to be separate diseases, but are now understood to be opposite ends of a spectrum of the same disease. They are both caused by a deficiency of the enzyme acid sphingomyelinase (ASM) and therefore are known as Acid Sphingomyelinase Deficiency (ASMD) Niemann-Pick disease. Many variations exist within this spectrum, in terms of clinical symptoms and rate of progression.
NP-A is a rare inherited lysosomal storage disorder in which harmful quantities of a fatty substance called sphingomyelin build up in the body’s cells and organs. In NP-B this build up mainly occurs in the liver, spleen and lungs. However, in NP-A build up also occurs in the brain leading to aggressive neurological problems. A small number of patients may be described as having A/B variant, falling in the middle of the spectrum and exhibiting neurological problems which may become more apparent over time.
It is inherited when two copies of a faulty gene (a mutation) are passed on to a child. In every pregnancy of a couple who each carry a copy of the faulty Niemann-Pick gene, there is a 1 in 4 chance (25%) that their child will have Niemann-Pick disease. This is known as autosomal recessive inheritance.
There are three common mutations that account for NP-A in the Ashkenazi Jewish population, and the estimated incidence is ~1 in 40,000. The incidence in other populations is not known, but it is considered extremely rare and estimated to be about 1 in 10 million.
Sadly, in most cases of NP-A life expectancy rarely exceeds three years of age.
Niemann-Pick Disease Type A (NP-A) is caused by a severe deficiency of the enzyme acid sphingomyelinase. This is required to break down a fatty substance called sphingomyelin. Failure to break down sphingomyelin causes an accumulation within brain cells causing cell death and the enlargement of the liver and spleen.
Niemann-Pick Disease Type A (NP-A) is diagnosed by measuring the level of the enzyme acid sphingomyelinase, in the white blood cells. This can be done by testing a small blood sample. The diagnosis is usually confirmed by DNA sequencing to identify mutations.
The enzyme deficiency at the cause of NP-A arises from mutations (or gene faults) in a gene on chromosome 11. An affected person will have inherited two faulty genes, one on each chromosome 11.
Symptoms of Niemann-Pick Disease Type A (NP-A) develop within the first few months of life and may include a combination of:
There are no specific treatment, or cure, for Niemann-Pick Disease Type A (NP-A). However, patients will benefit from palliative treatments (individual medications that will help to treat the symptoms related to the condition).
OXFORD, UK / ACCESSWIRE / January 15, 2020 / IntraBio Inc., a late-stage biopharmaceutical company, is pleased to share that the Extension Phase for the IB1001-201 Clinical Trial has been approved in all European countries where the trial is being conducted...Read more